The Saudi Arabia Neurology Clinical Trials market is projected to grow from $88.9 Mn in 2022 to $152.8 Mn by 2030, registering a CAGR of 7% during the forecast period of 2022 - 2030. The market will be driven by the high prevalence of neurological disorders, and increasing investment in healthcare infrastructure. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Novartis AG & Tabuk Pharmaceuticals.
The Saudi Arabia Neurology Clinical Trials market is projected to grow from $88.9 Mn in 2022 to $152.8 Mn by 2030, registering a CAGR of 7% during the forecast period of 2022 - 2030. Saudi Arabia does spend a major portion of its yearly budget on healthcare, around 16 %, and the country has made the highest healthcare infrastructure expenditures internationally between 2010 and 2020, according to a recent Gulf Cooperation Council (GCC) study. The percentage of the population aged 65 and over in Saudi Arabia is anticipated to rise from 1.169 million (3.4%) in 2020 to 7.681 million (17.2%) by 2050. The incidence of stroke in Saudi Arabia is 43.8 per 100,000. According to research released in August 2020 titled 'Assessment of knowledge of Alzheimer's disease among health university students in Riyadh, Saudi Arabia,' the incidence of dementia in Saudi Arabia is projected to be approximately 6.4%.
Saudi Arabia's neurology clinical trials business is expanding gradually. In recent years, the government has achieved great progress in terms of infrastructure development as well as the establishment of legislation and norms to facilitate clinical research. This has contributed to the creation of a suitable atmosphere in the nation for the conduct of neurology clinical trials. The government also has the Saudi Clinical Trials Network (SNCT) which intends to improve the quality and number of clinical trials done in Saudi Arabia.
Market Growth Drivers
Saudi Clinical Trials Network (SNCT) The SNCT intends to improve the quality and number of clinical trials done in Saudi Arabia via two major projects: one geared at developing the kingdom's legal and regulatory framework to reduce bureaucracy, and the other at training and retaining the requisite personnel. The SNCT emphasises recruiting and retaining clinical trial talent inside the kingdom via a training programme and by bringing in foreign specialists to teach present and future Saudi clinical research workers.
The Saudi Food and Drug Authority (SFDA) has created clinical trial standards and procedures, which have aided in the expansion of clinical research in the kingdom. The high frequency of neurological illnesses in Saudi Arabia offers a huge population pool for clinical studies. The Saudi government has made significant investments in healthcare infrastructure, allowing for the construction of cutting-edge medical facilities and the recruitment of top healthcare specialists. Pharmaceutical firms are increasingly interested in conducting clinical trials in Saudi Arabia, which has encouraged the clinical trials market's growth. All of the mentioned factors contribute to the growth of the market in Saudi Arabia.
Market Restraints
Cultural and religious barriers may make it difficult to enrol people for clinical trials, especially those involving invasive procedures or novel therapies. Patients may be unaware of clinical studies or their potential advantages, making it difficult to attract participants. Researchers may have restricted access to financing for clinical studies, which may hinder market expansion. Moreover, A scarcity of trained employees in some sectors, such as data management and clinical trial coordination, might hinder market development.
Key Players
October 2022, Zhittya Genesis Medical, Inc. (a private firm) ("Zhittya") offered an educational luncheon session regarding its medical findings for the treatment of Parkinson's disease in Jeddah, Saudi Arabia.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
6. Methodology and Scope
By Phase (Revenue, USD Billion):
By Study Design Outlook (Revenue, USD Billion):
By Indication Outlook (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.